From Bloomberg Markets and Finance.

Novo Nordisk won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly. President and CEO Mike Doustdar says he sees the market expanding as the pill goes on sale